drugset / Trial / NCT04066244
Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients
RandomizedSequentialOpen-labelTreatment
Summary
It was an open label study to evaluate safety, tolerability and brain microglia response in participants with Amyotrophic Lateral Sclerosis (ALS) following multiple doses of BLZ945.
Timeline
- Start
- 2019-12-30
- Primary completion
- 2024-02-01
- Completion
- 2024-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SOTULETINIB | Small molecule | 300 mg | Oral |
| Subject | SOTULETINIB | Small molecule | 600 mg | Oral |
| Subject | SOTULETINIB | Small molecule | 800 mg | Oral |
| Subject | SOTULETINIB | Small molecule | 1200 mg | Oral |